Search results
Showing 1141 to 1155 of 1334 results for long term conditions
Rifaximin for preventing episodes of overt hepatic encephalopathy (TA337)
Evidence-based recommendations on rifaximin (Targaxan) for preventing episodes of hepatic encephalopathy in adults.
NICE appoints Dr Adrian Hayter as its new chief medical officer
Dr Adrian Hayter joins NICE from the Royal College of General Practitioners bringing more than three decades of frontline clinical and national leadership experience to the role.
MRI-based technologies for assessing non-alcoholic fatty liver disease (HTG655)
Evidence-based recommendations on MRI-based technologies for assessing non-alcoholic fatty liver disease.
rehabilitation programmes are an established treatment strategy for certain heart conditions, such as for people who have had a heart...
'I no longer feel asthmatic': more than a million people now using new style inhalers
The change follows a landmark guideline published jointly in 2024 by NICE, the British Thoracic Society (BTS) and the Scottish Intercollegiate Guidelines Network (SIGN).
Evidence-based recommendations on imatinib for treating unresectable or metastatic gastrointestinal stromal tumours in adults.
Cetuximab and panitumumab for previously untreated metastatic colorectal cancer (TA439)
Evidence-based recommendations on cetuximab (Erbitux) and panitumumab (Vectibix) for previously untreated RAS wild-type metastatic colorectal cancer in adults.
Evidence-based recommendations on viscoelastometric point-of-care testing devices (the ROTEM, TEG and Sonoclot systems).
Dapagliflozin for treating chronic heart failure with reduced ejection fraction (TA679)
Evidence-based recommendations on dapagliflozin (Forxiga) for symptomatic chronic heart failure with reduced ejection fraction in adults.
Evidence-based recommendations on avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy in adults.
other conditions after discharge from hospital. Full details of the evidence and the committee's discussion are in evidence review Q:...
Evidence-based recommendations on lutetium-177 vipivotide tetraxetan (Pluvicto) for treating prostate-specific membrane antigen-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments in adults.
Health Technology Assessment Innovation Laboratory (HTA Lab)
NICE's HTA Lab enables us to develop creative solutions to complex problems in health technology assessment.
Extracorporeal carbon dioxide removal for acute respiratory failure (HTG703)
Evidence-based recommendations on extracorporeal carbon dioxide removal for acute respiratory failure. This involves taking blood out of the circulatory system and passing it across a synthetic membrane that allows some of the carbon dioxide in the blood to be removed. The blood is then returned to the circulatory system.
View recommendations for HTG703Show all sections